Literature DB >> 7891160

Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.

A M Murray1, T M Hyde, M B Knable, M M Herman, L B Bigelow, J M Carter, D R Weinberger, J E Kleinman.   

Abstract

The identification of five dopamine receptor subtypes has given the dopamine hypothesis of schizophrenia new life. The D4 receptor is particularly intriguing because it binds clozapine with high affinity. Putative D4 receptors were labeled in postmortem human brain by subtracting the binding of a saturating concentration of 3H-raclopride (6 nM, which labels D2 and D3 receptors) from that labeled by a saturating concentration of [3H]YM 09151-2 (1-1.3 nM, which labels D2, D3, and D4 receptors). In the control brain, putative D4 receptors show a homogenous distribution in striatum and nucleus accumbens. This is also true in schizophrenic brains, although the levels are significantly higher (twofold). These data are inconsistent with mRNA studies that have shown negligible amounts in striatum and accumbens, with modest amounts reported in most of cerebral cortex. These findings suggest that the putative D4 receptors are not synthesized in this region, but are presynaptically localized on striatal afferent terminals. Our findings confirm and extend the report of Seeman et al. (1993). Extension of these findings into the nucleus accumbens is important because of its extensive connections to the limbic system while the putamen is exclusively "motor" striatum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7891160      PMCID: PMC6578159     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  16 in total

1.  D4 dopamine and metabotropic glutamate receptors in cerebral cortex and striatum in rat brain.

Authors:  M A Berger; M C Defagot; M J Villar; M C Antonelli
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

2.  Autoradiographic localization of the putative D4 dopamine receptor in rat brain.

Authors:  M C Defagot; M C Antonelli
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

3.  Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.

Authors:  Toshikazu Ikuta; Delbert G Robinson; Juan A Gallego; Bart D Peters; Patricia Gruner; John Kane; Majnu John; Serge Sevy; Anil K Malhotra; Philip R Szeszko
Journal:  Psychiatry Res       Date:  2013-10-10       Impact factor: 3.222

4.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

Review 5.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 6.  The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions.

Authors:  S Totterdell
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

7.  Coordinated expression of dopamine receptors in neostriatal medium spiny neurons.

Authors:  D J Surmeier; W J Song; Z Yan
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

Review 8.  Executive function, neural circuitry, and genetic mechanisms in schizophrenia.

Authors:  Daniel Paul Eisenberg; Karen Faith Berman
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 9.  Synapse-specific contributions in the cortical pathology of schizophrenia.

Authors:  Saurav Seshadri; Mariela Zeledon; Akira Sawa
Journal:  Neurobiol Dis       Date:  2013-01-18       Impact factor: 5.996

10.  Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia.

Authors:  Eiji Hattori; Mizuho Nakajima; Kazuo Yamada; Yoshimi Iwayama; Tomoko Toyota; Naruya Saitou; Takeo Yoshikawa
Journal:  Eur J Hum Genet       Date:  2008-12-17       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.